iBio (IBIO) risk factors
Item 1A of every iBio, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors70 risks18 new11 dropped14 reworded
IBIO-600 is now in a Phase 1 Australian trial, adding country-specific regulatory, enrollment, CRO and FDA-data-acceptance exposure.
Filed Aug 28, 2026 - FY2025 10-K risk factors63 risks18 new10 dropped10 reworded
iBio faces severe going concern risks with an accumulated deficit of $332.2 million as of June 30, 2025. Raising capital is constrained because its public float dropped to approximately $20.0 million, well below the $75.0 million threshold. All product candidates remain in preclinical development, focusing primarily on cardiometabolic and obesity fields.
Filed Sep 05, 2025 - FY2024 10-K risk factors55 risks
The risk profile is dominated by severe liquidity concerns, ongoing operating losses, and a looming going concern doubt. The company faces high dependence on third-party manufacturers, unproven artificial intelligence drug discovery technologies, and early-stage preclinical assets. Operations are threatened by the need for additional capital raising, which risks significant dilution for existing stockholders.
Filed Sep 20, 2024